KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biocryst Pharmaceuticals (BCRX) Receivables - Net (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Receivables - Net readings, the most recent being $10.5 million for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 371.93% to $10.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.5 million, a 371.93% increase, with the full-year FY2025 number at $10.5 million, up 371.93% from a year prior.
  • Receivables - Net hit $10.5 million in Q4 2025 for Biocryst Pharmaceuticals, down from $91.3 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $93.4 million in Q1 2025 to a low of $1.0 million in Q3 2024.
  • Median Receivables - Net over the past 5 years was $14.4 million (2021), compared with a mean of $27.5 million.
  • Biggest five-year swings in Receivables - Net: tumbled 96.1% in 2024 and later soared 9032.5% in 2025.
  • Biocryst Pharmaceuticals' Receivables - Net stood at $29.4 million in 2021, then soared by 72.03% to $50.6 million in 2022, then increased by 12.55% to $57.0 million in 2023, then tumbled by 96.1% to $2.2 million in 2024, then skyrocketed by 371.93% to $10.5 million in 2025.
  • The last three reported values for Receivables - Net were $10.5 million (Q4 2025), $91.3 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.